Table of Contents
ISRN Cardiology
Volume 2013, Article ID 903454, 11 pages
Review Article

Human Immunodeficiency Virus and Pulmonary Arterial Hypertension

Department of Internal Medicine, Saint Joseph Hospital, 2900 North Lake Shore, Chicago, LL 60657, USA

Received 27 June 2013; Accepted 23 July 2013

Academic Editors: B. Strasberg and A. Szekely

Copyright © 2013 Aibek E. Mirrakhimov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Human immunodeficiency virus- (HIV-) related pulmonary arterial hypertension (PAH) is a rare complication of HIV infection. The pathophysiology of HIV-related PAH is complex, with viral proteins seeming to play the major role. However, other factors, such as coinfection with other microorganisms and HIV-related systemic inflammation, might also contribute. The clinical presentation of HIV-related PAH and diagnosis is similar to other forms of pulmonary hypertension. Both PAH-specific therapies and HAART are important in HIV-related PAH management. Future studies investigating the pathogenesis are needed to discover new therapeutic targets and treatments.